Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable ...

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

Asked where AI is having the biggest impact in digital engagement, around half (49%) of respondents said it was in data ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Indian pharma grapples headwinds of US pricing reform & Europe’s HTA-driven cost-effectiveness: Akash Kedia: Nandita Vijayasimha, Bengaluru Monday, June 9, 2025, 08:00 Hrs [IST] ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. We sell ...

Treatment Market is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot upwards of USD 25,375.6 million. As ...

Troyen A. Brennan, Harvard University. Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However ...